Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that ...
BOSTON, May 23, 2024--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer ...
– The phase 1/2 clinical trial of TNG348, a USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts – – Cash runway extended into 2027, PRMT5 and CoREST clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback